Search
MB-07803
go.drugbank.com/drugs/DB05053InvestigationalMB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.
Cetilistat
go.drugbank.com/drugs/DB06586InvestigationalCetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.
Girentuximab
go.drugbank.com/drugs/DB05304InvestigationalGirentuximab is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC).
Washed Microbiota Transplantation
go.drugbank.com/drugs/DB15745InvestigationalFecal microbiota transplantation (FMT) is effective in enhancing the gut microbiota of patients experiencing a high range of disease states, including Clostridioides difficile (C. diff) infection, Crohn’s disease, and ulcerative colitis....
AK119
go.drugbank.com/drugs/DB16423InvestigationalAK119 is a humanized anti-CD73 monoclonal antibody being investigated in the clinical trial NCT04516564 (A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects).
Oxantel
go.drugbank.com/drugs/DB13670InvestigationalOxantel is an anthelmintic drug that targets parasitic acetylcholine receptors.
Eniluracil
go.drugbank.com/drugs/DB03516InvestigationalEniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’s most widely-used oncology agents. ...
FM-VP4
go.drugbank.com/drugs/DB05449InvestigationalFM-VP4, is a novel hydrophilic phytostanol analogue representing a new class in cholesterol-lowering drugs called cholesterol absorption inhibitors. FM-VP4 has been shown to inhibit cholesterol absorption and to lower plasma LDL-choleste...
Bortezomib
go.drugbank.com/drugs/DB00188ApprovedInvestigationalBortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome ...